Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Mark Schreuder, MD, Daniel Verhoef, MSc, Ka Lei Cheung, Koen Visscher, MSc, Daan Geerke, PhD, Pieter H. Reitsma, PhD, Mettine H.A. Bos, PhD

Blood (2017) 130 (Supplement 1): 363.

https://doi.org/10.1182/blood.V130.Suppl_1.363.363

Published: 2017

Journal Articles

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Daniël Verhoef, Mark Schreuder, Ka Lei Cheung, Pieter H. Reitsma, Mettine H.A. Bos, PhD

Blood (2015) 126 (23): 126.

https://doi.org/10.1182/blood.V126.23.126.126

Published: 2015

Journal Articles

Modulating the Factor V Procofactor to Cofactor Transition Using Recombinant B-Domain Fragments

Matthew W Bunce, PhD, Mettine H.A. Bos, PhD, Rodney M. Camire, PhD

Blood (2011) 118 (21): 376.

https://doi.org/10.1182/blood.V118.21.376.376

Published: 2011

Journal Articles

Molecular Mechanism Underlying the Need for Three Cleavage Sites within the B-Domain to Activate Factor V by Thrombin

Roisin Walshe, BS, Mettine H.A. Bos, PhD, Rodney M. Camire, PhD

Blood (2010) 116 (21): 2219.

https://doi.org/10.1182/blood.V116.21.2219.2219

Published: 2010

Journal Articles

Venom-Derived Factor V from the Common Brown Snake P. Textilis Is Expressed as a Constitutively Active Cofactor.

Mettine H.A. Bos, PhD, Michael Boltz, Liam St. Pierre, PhD, Martin F. Lavin, PhD, Rodney M. Camire, PhD

Blood (2007) 110 (11): 1765.

https://doi.org/10.1182/blood.V110.11.1765.1765

Published: 2007

NARROW

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Modulating the Factor V Procofactor to Cofactor Transition Using Recombinant B-Domain Fragments

Molecular Mechanism Underlying the Need for Three Cleavage Sites within the B-Domain to Activate Factor V by Thrombin

Venom-Derived Factor V from the Common Brown Snake P. Textilis Is Expressed as a Constitutively Active Cofactor.

Email alerts

ASH Publications

American Society of Hematology

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Phe174-Mutated Human Factor X As Bypassing Agent to the Direct FXa Inhibitors

Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa-Inhibitors

Modulating the Factor V Procofactor to Cofactor Transition Using Recombinant B-Domain Fragments

Molecular Mechanism Underlying the Need for Three Cleavage Sites within the B-Domain to Activate Factor V by Thrombin

Venom-Derived Factor V from the Common Brown Snake P. Textilis Is Expressed as a Constitutively Active Cofactor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only